Gan & Lee Pharmaceuticals (603087.SH): First subject in Phase II clinical trial of GZR102 injection completed dosing.

Gan & Lee Pharmaceuticals (603087.SH) announced that its wholly-owned subsidiary Gan & Lee Pharmaceuticals Shandong Co., Ltd. has initiated Phase II clinical trials in China for GZR102 injection, an investigational product developed independently by the company. Recently, the first dose of the drug was successfully administered to a participant. GZR102 injection is a fixed-ratio combination formulation of basal insulin/GLP-1RA, consisting of the fixed ratio combination of the insulin secretagogue GZR4 and the GLP-1RA exenatide. Administered as a once-weekly subcutaneous injection, GZR102 maximizes the synergistic effects of both drug components through an innovative formulation. The combination therapy of GLP-1RA and insulin can address multiple pathological and physiological defects of type 2 diabetes, enhancing glycemic control while reducing the daily insulin requirement and mitigating adverse effects such as hypoglycemia and weight gain. It is expected to offer an effective, safe, and convenient treatment option for patients with type 2 diabetes. Currently, the global development of GZR102 has entered Phase II clinical trials.